Lv31
270 积分 2022-02-18 加入
[Advances in diagnosis and treatment and whole process management of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer]
5小时前
求助中
Brigatinib activates inflammasomes: Implication for immune-related adverse events
11天前
已完结
Therapeutic effects of an ALK inhibitor, brigatinib, on lung large cell neuroendocrine carcinoma with EML4-ALK fusion
1个月前
已完结
Unlocking the Next Frontier in Precision Oncology: Addressing Drug-Tolerant Residual Disease
4个月前
已完结
Auxological outcome and time to menarche following long‐acting goserelin therapy in girls with central precocious or early puberty
6个月前
已完结
Accelerated Versus Slowly Progressive Forms of Puberty in Girls with Precocious and Early Puberty. Gonadotropin Suppressive Effect and Final Height Obtained with Two Different Analogs
6个月前
已完结
Comparison of Two Different Gnrh Analogs’ Impact on Final Height in Girls with Early Puberty: Triptorelin Acetate vs. Leuprolide Acetate
6个月前
已关闭
Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort study
7个月前
已完结
Different dosage forms of GnRHa with endocrine therapy in premenopausal hormone Receptor-Positive breast cancer
10个月前
已完结
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study
11个月前
已完结
皖公网安备34019202002308
